Insilico announces positive phase 1 trial results for AI-designed IPF drug
Insilico Medicine, an AI biotech company, announced positive results from the Phase 1 clinical trial of INS018_055, its first-in-class drug for idiopathic pulmonary fibrosis.
Drugs
Pharma
Drugs
Pharma
Sanofi signs $1.2 billion drug discovery agreement with Insilico
Sanofi signs $1.2 billion drug discovery deal with AI driven drug startup Insilico